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Introduction 
Toxic erythema of chemotherapy (TEC) caused by 
thiotepa typically manifests as localized cutaneous 
erythema, hyperpigmentation, or oropharyngeal 
mucositis and stomatitis [1-5]. Although thiotepa 
toxicity is known to demonstrate a preference for 
intertriginous sites, a clinical presentation known as 
malignant intertrigo [6], to our knowledge there has 
not previously been reported a case involving 
extensive areas of intertriginous and occluded areas 
so as to mimic early Stevens-Johnson syndrome (SJS) 
or toxic epidermal necrolysis (TEN). Herein, we 
present a patient with SJS-like mucositis, erythema, 
and desquamation in occluded areas. The patient 
had been undergoing thiotepa-based conditioning 
chemotherapy for diffuse large B-cell lymphoma and 
the eruption was consistent with thiotepa-induced 
malignant intertrigo. 
 
Case Synopsis 
A 71-year-old man with diffuse large B-cell 
lymphoma involving the right frontal operculum was 
admitted for conditioning chemotherapy and 
autologous stem cell transplant (ASCT). The patient 
had completed two initial cycles of cytarabine and 
thiotepa, TBC (thiotepa, busulfan, and 
cyclophosphamide) conditioning, and subsequent 
ASCT. A dermatology consultation was requested 
eleven days post-transplantation for evaluation for 
Abstract 
Thiotepa is a common alkylating agent known to 
precipitate cutaneous reactions consistent with toxic 
erythema of chemotherapy, including erythema and 
hyperpigmentation. Herein, we describe an atypical 
case of malignant intertrigo involving preferential 
erythema and desquamation not only of skin folds 
but also of occluded areas after thiotepa-based 
conditioning. The diagnosis was complicated by 
concurrent stomatitis and oral petechiae in the 
setting of autologous stem cell transplant 11 days 
prior for diffuse large B-cell lymphoma. 
Histopathological examination from two cutaneous 
sites demonstrated epidermal dysmaturation and 
eccrine gland necrosis consistent with thiotepa-
induced desquamation and not Stevens-Johnson 
syndrome or graft-versus-host-disease. Malignant 
intertrigo can present with extensive cutaneous 
involvement, as evidenced by our patient who had 
25% body surface area affected. Mucosal 
involvement is common with most 
chemotherapeutic regimens and its presence should 
not deter the astute clinician from consideration of a 
diagnosis of toxic erythema of chemotherapy. No 
further interventions were needed and the patient 
healed spontaneously. 
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presumed SJS-TEN overlap. History from family 
members confirmed that previous to desquamation 
the patient had localized erythema in areas of 
occlusion. 
Initial examination revealed an afebrile, ill-
appearing, intubated, supine man with dusky 
erythema and overlying superficial erosions on the 
neck, bilateral axillae, back, buttocks, and thighs 
involving about 25% of his body surface area (BSA), 
(Figure 1). In the mouth, scattered petechiae on the 
hard palate and crusting along the superior labial 
mucosa were found. Laboratory tests were notable 
for pancytopenia, including a white blood cell count 
of 3.85×103/uL and an absolute lymphocyte count of 
0.4×103/uL, elevated BUN (52mg/dL), and depressed 
liver function enzymes (ALT 5U/L; AST 12U/L). 
Microbiology results (viral, bacterial, atypical 
mycobacterial, and fungal cultures of blood and 
tissue) showed no growth. Two punch biopsies (from 
the mid back and thigh) were performed given initial 
concern for drug induced hypersensitivity 
syndrome, SJS/TEN and early graft versus host 
disease (GVHD). Biopsies revealed mild superficial 
perivascular mixed-inflammatory infiltrate, with 
notable absence of eosinophils (Figure 2). Scattered 
apoptotic foci and keratinocyte and eccrine sweat 
gland necrosis accompanied consistent epidermal 
dysmaturation. No intracellular inclusions were seen. 
Thus, based on clinical and histopathologic 
evaluation, a diagnosis of thiotepa-induced 
malignant intertrigo was made. 
Given the self-healing nature of the condition, no 
further treatment was recommended. Over the 
subsequent three weeks, the skin desquamated and 
then re-epithelialized. 
 
Case Discussion 
Thiotepa is a common alkylating agent for the 
treatment of lymphomas, central nervous system 
tumors, and pediatric solid tumors long identified as 
Figure 1. Day of presentation: dusky erythema and 
hyperpigmentation around sites of desquamation. A) buttocks, 
and B) left axilla. 
Figure 2. Hematoxylin-eosin skin biopsy pathology revealed 
interface dermatitis with epidermal dysmaturation and foci of 
keratinocyte necrosis consistent with a thiotepa-induced drug 
reaction, 200×. 
A 
B 
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a cause of dermatologic cytotoxicity, or toxic 
erythema of chemotherapy (TEC), [1]. One 
retrospective study of 38 pediatric patients revealed 
a distinct sequence and distribution to the skin 
reactions, which progress from mild erythema to 
generalized erythema, hyperpigmentation, and 
desquamation in intertriginous areas; truncal and 
occluded areas may also be involved [3]. This 
constellation of painful erythema, maceration, and 
subsequent erosion and desquamation localizing to 
intertriginous and occluded regions defines the 
unique pattern of TEC known as malignant intertrigo 
[6]. Our patient followed the well-documented 
natural course of thiotepa-induced malignant 
intertrigo. However, in addition to the intertriginous 
distribution of affected skin the patient also had 
involvement of occluded areas and more broad 
involvement of 25% of his BSA. Hyperpigmented 
patches, edematous plaques, and scaly surface 
changes have been noted in other reports but were 
not prominent in this case. 
Preferential destruction at occluded zones is 
believed to reflect accumulation and excretion of 
various chemotherapeutics through eccrine sweat 
glands [2]. Consistent with this feature is the eccrine 
gland necrosis noted on histologic examination. 
Described in the context of various underlying 
malignancies and chemotherapeutics (most notably 
doxorubicin), malignant intertrigo is a self-limited 
condition appropriately managed with symptomatic 
control, wound care, and in severe cases, adjustment 
of the chemotherapy regimen [6, 7]. Our patient was 
treated with supportive care alone utilizing xeroform 
gauze and his eruption resolved over the ensuing 
weeks. 
Initial concern for SJS/TEN and GVHD was high in this 
patient given the mucosal involvement atypical of 
classic malignant intertrigo. Unlike toxic erythema of 
chemotherapy, Stevens-Johnson syndrome-
spectrum disorders follow a malignant course with 
up to 34% mortality reported in some studies and 
necessitates immediate withdrawal of offending 
agent(s), [8]. Thus, the histopathologic distinction 
between thiotepa-induced skin reactions and SJS or 
TEN is crucial for maintaining optimal drug regimens 
and evaluating patient prognosis. Herein, a lack of 
partial-to-full thickness epidermal necrosis or 
satellite lymphocyte necrosis made SJS or GVHD 
unlikely diagnoses, respectively. 
 
Conclusion 
This case highlights a presentation of thiotepa-
induced toxic erythema, including synchronous 
malignant intertrigo and mucositis, that mimicked 
early SJS. Malignant intertrigo from thiotepa should 
be distributed predominantly in occluded areas such 
as the neck, axillae, inner thighs, and, for critically-ill 
patients in supine position, the back, and thus may 
cover an extensive BSA. Similarly, the presence of 
mucosal lesions and stomatitis should not deter 
clinical consideration for chemotherapy toxicity. 
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